Sen. Joe Manchin seeks to block new painkiller

U.S. Sen. Joe Manchin is calling on the government's top health official to overturn the approval of a powerful painkiller, arguing that the pill Zohydro could add to the national epidemic of prescription drug abuse.

The West Virginia Democrat joins a chorus of lawmakers, state prosecutors and medical groups seeking a reversal of the Food and Drug Administration's October approval. In a letter Monday, Manchin asks Health and Human Services Secretary Kathleen Sebelius to overrule the agency's decision.

Zohydro is the first single-ingredient hydrocodone drug ever cleared for U.S. patients. The extended-release pill contains more of the narcotic pain reliever than older combination pills, such as Vicodin.

The FDA approval surprised many doctors, since the agency's own advisers voted overwhelmingly against the drug, citing its abuse potential.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Potent new painkiller stokes alarm in US

Mar 08, 2014

A potent new painkiller hit the US market this week, despite warnings from top experts that the drug may deliver a deadly setback in America's battle with opioid addiction.

US panel opposes pure hydrocodone painkiller

Dec 09, 2012

(AP)—U.S. government health experts overwhelmingly voted against a stronger version of hydrocodone on Friday, questioning the need for a new form of one of most widely abused prescription painkillers.

Recommended for you

Determine patient preferences by means of conjoint analysis

15 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments